| abstract |
The present application provides evidence that a combined blockade against alpha-4 integrin and MCAM is more effective than against either molecule alone. In consequence, the invention provides methods of combination treatment in which both an antagonist of alpha-4 integrin and an MCAM antagonist are administered to a subject having or at risk of multiple sclerosis or other autoimmune disease. |